Wolfe Research began coverage on shares of GSK (NYSE:GSK – Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set an “outperform” rating and a $70.00 price target on the pharmaceutical company’s stock. Wolfe Research’s price target indicates a potential upside of 50.48% from the company’s current price.
A number of other analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Thursday, July 30th. Citigroup initiated coverage on GSK in a report on Friday, July 24th. They set a “neutral” rating on the stock. Morgan Stanley reissued an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Berenberg Bank set a $60.00 target price on GSK in a research report on Tuesday, September 15th. Finally, Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, GSK has an average rating of “Hold” and a consensus price target of $61.00.
View Our Latest Stock Report on GSK
GSK Stock Down 1.1%
GSK (NYSE:GSK – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. During the same period last year, the firm posted $0.47 EPS. The business’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts predict that GSK will post 4.79 earnings per share for the current fiscal year.
Hedge Funds Weigh In On GSK
Hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC increased its holdings in shares of GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after acquiring an additional 852,437 shares during the last quarter. Waverly Advisors LLC boosted its stake in GSK by 1,372.8% in the 2nd quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after purchasing an additional 270,863 shares during the period. Tidal Investments LLC grew its stake in shares of GSK by 4.6% in the second quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock valued at $11,545,000 after acquiring an additional 9,603 shares in the last quarter. Keystone Financial Planning Inc. grew its position in shares of GSK by 3,114.8% during the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares in the last quarter. Finally, QRG Capital Management Inc. increased its stake in GSK by 7.6% during the 2nd quarter. QRG Capital Management Inc. now owns 191,512 shares of the pharmaceutical company’s stock worth $10,039,000 after acquiring an additional 13,519 shares during the period. 15.74% of the stock is owned by institutional investors.
About GSK
GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.
GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.
Featured Stories
- Five stocks we like better than GSK
- JetBlue’s LaGuardia Win Could Change Its Financial Future
- Study Reveals 1 in 3 High Earners Think They Should Pay More Tax [2026]
- Wall Street Left Software for Dead: 4 Stocks Institutions Are Buying Back
- Alphabet and Unity Level Up Game Development
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
